Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy

Journal of Immunology

Volumn 170, Issue 12, 2003, Pages 6338-6347

  Chakraborty, Mala ^a   Abrams, Scott I ^a   Camphausen, Kevin ^a   Liu, Kebin ^a   Scott, Tamalee ^a   Coleman, C Norman ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; FAS ANTIGEN; FAS LIGAND;

ADENOCARCINOMA; ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; UPREGULATION;

EID: 0037942745     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.12.6338     Document Type: Article

References (60)

1. Rosenberg, S. A. 2001. Progress in the development of immunotherapy for the treatment of patients with cancer. J. Intern. Med. 250:462.
2. Rosenberg, S. A. 1999. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 10:281.
3. Cheever, M. A., P. D. Greenberg, and A. Fefer. 1984. Potential for specific cancer therapy with immune T lymphocytes. J. Biol. Response Mod. 3:113.
4. Riddell, S. R., E. H. Warren, D. Lewinsohn, H. Mutimer, M. Topp, L. Cooper, R. de Fries, and P. D. Greenberg. 2000. Application of T cell immunotherapy for human viral and malignant diseases. In Ernest Schering Res. Found. Workshop 30, Berlin. Springer, Berlin, p. 53.
5. Foss, F. M. 2002. Immunologic mechanisms of antitumor activity. Semin. Oncol. 29:5.
6. French, L. E., and J. Tschopp. 2002. Defective death receptor signaling as a cause of tumor immune escape. Semin. Cancer Biol. 12:51.
7. Yee, C., and P. Greenberg. 2002. Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat. Rev. Cancer 2:409.
8. Perez-Diez, A., and F. M. Marincola. 2002. Immunotherapy against antigenic tumors: a game with a lot of players. Cell. Mol. Life Sci. 59:230.
9. Owen-Schaub, L. 2002. Fas function and tumor progression: Use it and lose it. Cancer Cell 2:95.
10. Maecker, H., Z. Yun, and A. Giaccia. 2002. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2:139.
11. Gilboa, E. 1999. How tumors escape immune destruction and what we can do about it. Cancer Immunol. Immunother. 48:382.
12. Friedman, E. J. 2002. Immune modulation by ionizing radiation and its implications for cancer immunotherapy. Curr. Pharm. Des. 8:1765.
13. Garrido, F., and I. Algarra. 2001. MHC antigens and tumor escape from immune surveillance. Adv. Cancer Res. 83:117.
14. Quarmby, S., R. D. Hunter, and S. Kumar. 2000. Irradiation induced expression of CD31, ICAM-1 and VCAM-1 in human microvascular endothelial cells. Anticancer Res. 20:3375.
15. Uno, M., T. Otsuki, K. Yata, T. Fujii, H. Sakaguchi, T. Akisada, J. Hiratsuka, Y. Imajo, and T. Harada. 2002. Participation of Fas-mediated apoptotic pathway in KB, a human head and neck squamous cell carcinoma cell line, after irradiation. Int. J. Oncol. 20:617.
16. Abdulkarim, B., S. Sabri, E. Deutsch, S. Vaganay, E. Marangoni, W. Vainchenker, P. Bongrand, P. Busson, and J. Bourhis. 2000. Radiation-induced expression of functional Fas ligand in EBV-positive human nasopharyngeal carcinoma cells. Int. J. Cancer 86:229.
17. Albanese, J., and N. Dainiak. 2000. Ionizing radiation alters Fas antigen ligand at the cell surface and on exfoliated plasma membrane-derived vesicles: implications for apoptosis and intercellular signaling. Radiat. Res. 153:49.
18. Sheard, M. A., B. Vojtesek, L. Janakova, J. Kovarik, and J. Zaloudik. 1997. Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. Int. J. Cancer 73:757.
19. Nikitina, E. Y., and D. I. Gabrilovich. 2001. Combination of γ-irradiation and dendritic cell administration induces a potent antitumor response in tumor-bearing mice: approach to treatment of advanced stage cancer. Int. J. Cancer 94:825.
20. Cao, Z., D. Daniel, and D. Hanahan. 2002. Sub-lethal radiation enhances antitumor immunotherapy in a transgenic mouse model of pancreatic cancer. BMC Cancer 2:11.
21. Van Parijs, L., and A. K. Abbas. 1996. Role of Fas-mediated cell death in the regulation of immune responses. Curr. Opin. Immunol. 8:355.
22. Van Parijs, L., D. A. Peterson, and A. K. Abbas. 1998. The Fas/Fas ligand pathway and Bcl-2 regulate T cell responses to model self and foreign antigens. Immunity 8:265.
23. van Parijs, L., V. L. Perez, and A. K. Abbas. 1998. Mechanisms of peripheral T cell tolerance. Novartis Found. Symp. 215:5.
24. Nagata, S. 1996. Fas-mediated apoptosis. Adv. Exp. Med. Biol. 406:119.
25. Nagata, S. 1996. Fas-induced apoptosis, and diseases caused by its abnormality. Genes Cells 1:873.
26. Lenardo, M., K. M. Chan, F. Hornung, H. McFarland, R. Siegel, J. Wang, and L. Zheng. 1999. Mature T lymphocyte apoptosis: immune regulation in a dynamic and unpredictable antigenic environment. Annu. Rev. Immunol. 17:221.
27. Siegel, R. M., F. K. Chan, H. J. Chun, and M. J. Lenardo. 2000. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat. Immunol. 1:469.
28. Henkart, P. A., and M. V. Sitkovsky. 1994. Cytotoxic lymphocytes: two ways to kill target cells. Curr. Biol. 4:923.
29. Atkinson, E. A., and R. C. Bleackley. 1995. Mechanisms of lysis by cytotoxic T cells. Crit. Rev. Immunol. 15:359.
30. Sarin, A., E. K. Haddad, and P. A. Henkart. 1998. Caspase dependence of target cell damage induced by cytotoxic lymphocytes. J. Immunol. 161:2810.
31. Henkart, P. A., M. S. Williams, C. M. Zacharchuk, and A. Sarin. 1997. Do CTL kill target cells by inducing apoptosis? Semin. Immunol. 9:135.
32. Russell, J. H., and T. J. Ley. 2002. Lymphocyte-mediated cytotoxicity. Annu. Rev. Immunol. 20:323.
33. + T-cell epitope, which mediates tumor killing in CEA transgenic mice. Cancer Res. 62:5058.
34. Schlom, J., K. Y. Tsang, J. A. Kantor, S. I. Abrams, S. Zaremba, J. Greiner, and J. W. Hodge. 1999. Strategies in the development of recombinant vaccines for colon cancer. Semin. Oncol. 26:672.
35. Schlom, J., J. Kantor, S. Abrams, K. Y. Tsang, D. Panicali, and J. M. Hamilton. 1996. Strategies for the development of recombinant vaccines for the immunotherapy of breast cancer. Breast Cancer Res. Treat. 38:27.
36. Hodge, J. W. 1996. Carcinoembryonic antigen as a target for cancer vaccines. Cancer Immunol. Immunother. 43:127.
37. Eades-Perner, A. M., H. van der Putten, A. Hirth, J. Thompson, M. Neumaier, S. von Kleist, and W. Zimmermann. 1994. Mice transgenic for the human carcinoembryonic antigen gene maintain its spatiotemporal expression pattern. Cancer Res. 54:4169.
38. Grosenbach, D. W., J. C. Barrientos, J. Schlom, and J. W. Hodge. 2001. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects. Cancer Res. 61:4497.
39. Robbins, P. F., J. A. Kantor, M. Salgaller, P. H. Hand, P. D. Femsten, and J. Schlom. 1991. Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 51:3657.
40. + cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant. Cancer Immunol. Immunother. 49:603.
41. Muraro, R., D. Wunderlich, A. Thor, J. Lundy, P. Noguchi, R. Cunningham, and J. Schlom. 1985. Definition by monoclonal antibodies of a repertoire of epitopes on carcinoembryonic antigen differentially expressed in human colon carcinomas versus normal adult tissues. Cancer Res. 45:5769.
42. Esquivel, F., J. Yewdell, and J. Bennink. 1992. RMA/S cells present endogenously synthesized cytosolic proteins to class 1-restricted cytotoxic T lymphocytes. J. Exp. Med. 175:163.
43. Wunderlich, J., and G. Shearer. 1994. Induction and measurement of cytotoxic T lymphocyte activity. In Current Protocols in Immunology. J. Colligan, D. Kruisbeek, D. Margulies, E. Shevach, and W. Strober, eds. John Wiley & Sons, New York, p. 3.11.1.
44. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J. W. Greiner. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59:676.
45. Kantor, J., S. Abrams, K. Irvine, P. Snoy, H. Kaufman, and J. Schlom. 1993. Specific immunotherapy using a recombinant vaccinia virus expressing human carcinoembryonic antigen. Ann. NY Acad. Sci. 690:370.
46. Hareyama, M., K. Imai, T. Ban, H. Koshiba, K. Kubo, M. Shidou, A. Oouchi, and K. Morita. 1988. Effect of radiation on the expression of carcinoembryonic antigen on the membranes of human gastric adenocarcinoma cells: immunological study using monoclonal antibodies. Nippon Igaku Hoshasen Gakkai Zasshi 48:1572.
47. Ciernik, I. F., P. Romero, I. A. Berzofsky, and D. P. Carbone. 1999. Ionizing radiation enhances immunogenicity of cells expressing a tumor-specific T-cell epitope. Int. J. Radiat. Oncol. Biol. Phys. 45:735.
48. Gaugler, M. H., C. Squiban, A. van der Meeren, J. M. Bertho, M. Vandamme, and M. A. Mouthon. 1997. Late and persistent up-regulation of intercellular adhesion molecule-1 (ICAM-1) expression by ionizing radiation in human endothelial cells in vitro. Int. J. Radiat. Biol. 72:201.
49. Sheard, M. A. 2001. Ionizing radiation as a response-enhancing agent for CD95mediated apoptosis. Int. J. Cancer 96:213.
50. Owen-Schaub, L., H. Chan, J. C. Cusack, J. Roth, and L. L. Hill. 2000. Fas and Fas ligand interactions in malignant disease. Int. J. Oncol. 17:5.
51. Seki, N., A. D. Brooks, C. R. Carter, T. C. Back, E. M. Parsoneault, M. J. Smyth, R. H. Wiltrout. and T. J. Sayers. 2002. Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin. J. Immunol. 168:3484.
52. Kessler, B., D. Hudrisier, M. Schroeter, J. Tschopp, J. C. Cerottini, and I. F. Luescher. 1998. Peptide modification or blocking of CD8, resulting in weak TCR signaling, can activate CTL for Fas- but not perforin-dependent cytotoxicity of cytokine production. J. Immunol. 161:6939.
53. Hareyama, M., K. Imai, K. Kubo, H. Takahashi, H. Koshiba, Y. Hinoda, M. Shidou, A. Oouchi, A. Yachi, and K. Morita. 1991. Effect of radiation on the expression of carcinoembryonic antigen of human gastric adenocarcinoma cells. Cancer 67:2269.
54. Ganss, R., E. Ryschich, E. Klar, B. Arnold, and G. J. Hammerling. 2002. Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Res. 62:1462.
55. Yamamoto, T., K. Yoneda, E. Ueta, S. Doi, and T. Osaki. 2000. Enhanced apoptosis of squamous cell carcinoma cells by interleukin-2-activated cytotoxic lymphocytes combined with radiation and anticancer drugs. Eur. J. Cancer 36:2007.
56. Kessels, H. W., M. C. Wolkers, and T. N. Schumacher. 2002. Adoptive transfer of T-cell immunity. Trends Immunol. 23:264.
57. Cohen, P. A., L. Peng, J. Kjaergaard, G. E. Plautz, J. H. Finke, G. K. Koski, B. J. Czerniecki, and S. Shu. 2001. T-cell adoptive therapy of tumors: mechanisms of improved therapeutic performance. Crit. Rev. Immunol. 21:215.
58. Dudley, M. E., J. R. Wunderlich, P. F. Robbins, J. C. Yang, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, R. Sherry, N. P. Restifo, A. M. Hubicki, et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 298:850.
59. Hodge, J. W., H. Sabzevari, M. G. O. Korenz, A. Gomez Yafal, L. Gritz, and J. Schlom. 1999. A triad of costimulatory molecules synergize to amplify T cell activation. Cancer Res. 59:5800.
60. Marshall, J. L., N. Rizvi, E. Fox, and et al. 2001. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-TRICOM (B7/ICAM/LFA3) alone, and in combination with vaccinia-CEA (6D)- TRICOM and GM-CSF in patients with CEA expressing carcinomas. In AACR NC1 EORTC Conference on "Molecular Targets and Cancer Therapeutics. " Miami, Abstract 798.